Selling pressure pushes Moderna stock lower in today's trading

Traders Union
All News
Financial News
Moderna slips 2.14% today to $54.77

Highlights

Moderna settled ongoing mRNA patent disputes, reducing litigation risk and improving visibility on its intellectual property portfolio.
Jefferies Financial Group cut its Moderna stake by over 25% in Q3, signaling declining institutional confidence amid regulatory uncertainties around the mRNA flu vaccine.
Moderna’s price structure is bullish with momentum indicators overbought; expected consolidation between $52 and $54, with strong support at $52 and a high probability of upside continuation.

Patent settlements ease legal risk while regulatory signals sustain pressure

Moderna reduced its litigation risk by settling ongoing patent disputes related to its mRNA technologies. Jefferies Financial Group reported a 25.3% decrease in its stake in Moderna in the third quarter, now holding 95,266 shares valued at $2.46 million according to an SEC filing. Regulatory uncertainty persists due to ongoing FDA signals about the company’s new mRNA flu vaccine, and there were committee discussions in the U.S. related to vaccine recommendations, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees Moderna maintaining a bullish structure but notes the risk of an overextended rally. He points out that multiple momentum indicators, including RSI and CCI, signal overbought conditions and warn of a possible short-term pullback. Kharitonov emphasizes that regulatory uncertainty regarding mRNA flu approvals and broader selling pressure further increase downside risk. Recent institutional de-risking, as seen with Jefferies reducing its stake, adds a layer of caution. He remains skeptical of immediate upside. "Traders should be wary of chasing price at these levels, as technicals suggest limited room for further gains without a correction," Kharitonov says.

Viktoras Karapetjanc, expert at Traders Union, highlights a constructive macro and fundamental backdrop for Moderna. He notes the company’s resolution of litigation risks and views the current price action as healthy consolidation above key moving averages. Karapetjanc stresses that the bullish structure remains intact across timeframes and sees strong momentum confirmed by most technical indicators. The market offers multiple setups for further upside as regulatory headwinds begin to subside. "With the baseline scenario showing more than 80% probability of a price increase, I expect continued growth as Moderna builds on recent strengths," Karapetjanc states.

Momentum signals remain bullish despite short-term overbought caution

The current price of $54.77 is trading above the MA-20 at $50.20, the MA-50 at $44.19, and the MA-200 at $31.56, indicating clear bullish structure on short-, medium-, and long-term trends for Moderna. The nearest dynamic support is at the Ichimoku Kijun around $48.11, while resistance is set near the MA-50 at $44.19 and psychological zones above $55.

Momentum remains strong, with MACD and ADX both showing buy signals for the daily period. RSI at 63.48 points to ongoing buyer dominance but is approaching overbought territory, which is confirmed by CCI above 100 and a BBP reading indicating overbought conditions. Stoch RSI, however, signals a strong buy but remains moderate in value, reflecting some short-term buying potential. AO is neutral and does not add directional bias at this time. The price opened with a slight gap down from the previous close at $55.97 to $54.44 and is now trading mid-range within today’s band ($53.23–$54.96) after slipping 2.14% intraday. Volatility is moderate, and the tone suggests steady pressure after the open. Although overall momentum indicators are bullish, the overbought readings signal a minor divergence and caution for immediate upside.

Previously it was reported that Moderna Inc. is exhibiting strong bullish momentum, with its price significantly above key moving averages and supported by positive indicators such as MACD and ADX. However, several oscillators including RSI and Stoch RSI indicate overbought conditions, suggesting the potential for a near-term pullback with key support levels at the MA-50 and Ichimoku Kijun lines.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.